Processa Pharmaceuticals

Processa Pharmaceuticals Debt

The Debt of Processa Pharmaceuticals (PCSA) as of Oct 16, 2026 is 73,507.00 USD. In the previous year, Debt was 150,554.00 USD — a change of -51.18% (lower).

Debt

73,507.00USD

YoY

-51.18%

Last updated:

In 2024, Processa Pharmaceuticals's total debt was 73,507.00 USD, a -51.18% change from the 150,554.00 USD total debt recorded in the previous year.

The Processa Pharmaceuticals Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
2.45 M USD
Jan 1, 2018
230,000.00 USD
Jan 1, 2019
1.03 M USD
Jan 1, 2020
328,122.00 USD
Jan 1, 2021
78,463.00 USD
Jan 1, 2022
229,450.00 USD
Jan 1, 2023
150,554.00 USD
Jan 1, 2024
73,507.00 USD
The Processa Pharmaceuticals Debt history
YEARDebtYoY
73,507.00USD-51.18%
150,554.00USD-34.38%
229,450.00USD+192.43%
78,463.00USD-76.09%
328,122.00USD-68.08%
1.03 MUSD+346.91%
230,000.00USD-90.61%
2.45 MUSD+79.20%
1.37 MUSD0.00%
1.37 MUSD+42.25%
960,532.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Processa Pharmaceuticals Stock analysis

What does Processa Pharmaceuticals do? Processa Pharmaceuticals Inc, listed under ticker PCSA with ISIN US74275C4033, is headquartered in Hanover, Maryland, United States. The company operates in the Health Care sector within the Pharmaceuticals industry. It has 12 employees. Processa Pharmaceuticals went public on October 7, 2013. The company focuses on developing drug products to address serious medical conditions with unmet needs, targeting treatments for Necrobiosis Lipoidica and head and neck cancer effects. Processa Pharmaceuticals is one of the most popular companies on Eulerpool.

Debt Details

Understanding Processa Pharmaceuticals's Debt Structure

Processa Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Processa Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Processa Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Processa Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Processa Pharmaceuticals stock

Debt of Processa Pharmaceuticals is 73,507.00 USD in 2024.

Debt of Processa Pharmaceuticals changed from 150,554.00 USD to 73,507.00 USD, representing a -51.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Processa Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Processa Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Processa Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Processa Pharmaceuticals